Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$23.03 USD

23.03
629,434

-0.51 (-2.17%)

Updated May 8, 2024 04:00 PM ET

After-Market: $23.05 +0.02 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (90 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Prothena (PRTA) Alzheimer's Disease Drug Licensed by BMY

by Zacks Equity Research

Prothena (PRTA) will receive $55 million from Bristol Myers Squibb for an exclusive worldwide license to PRX005, designed for the potential treatment of Alzheimer's disease.

Biogen (BIIB), Eisai Get Full FDA Nod for Leqembi in Alzheimer's

by Zacks Equity Research

Following the full approval, Biogen (BIIB)/Eisai's Leqembi is the first approved treatment to slow progression of Alzheimer's disease. This also paves the way for a broader Medicare coverage.

Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement

by Zacks Equity Research

An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.

Biogen (BIIB), Eisai's Alzheimer Drug Likely to Get Full FDA Nod

by Zacks Equity Research

Based on briefing documents issued by the FDA, a full regulatory approval is expected on Biogen (BIIB)/Eisai's Alzheimer's disease antibody. The final decision is expected in the early next month.

Cassava (SAVA) Up on Progress With Alzheimers Disease Study

by Zacks Equity Research

Cassava (SAVA) made positive progress with simufilam, an oral drug treatment for Alzheimer's disease dementia. The company's shares gain in the last month.

Prothena (PRTA) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Prothena (PRTA) reports a wider loss in the first quarter. The company makes considerable pipeline progress.

Prothena (PRTA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -7.23% and 85.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Prothena (PRTA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Gains 29% in One Year: Will the Momentum Continue?

by Zacks Equity Research

Prothena (PRTA) surges 29% in the past one year as investors are optimistic on its promising Alzheimer's Disease pipeline.

Prothena (PRTA) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Prothena (PRTA) reports better-than-expected results for the fourth quarter. The company makes considerable pipeline progress.

Prothena (PRTA) Stock Gains 88.5% in 6 Months: What Lies Ahead?

by Zacks Equity Research

Prothena (PRTA) surges 88% in the last six months as investors are optimistic on its promising Alzheimer???s Disease pipeline.

Biogen (BIIB) Down on Report of Death in Alzheimer's Study

by Zacks Equity Research

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.

Prothena (PRTA) Earns Milestone Payment From Novo Nordisk

by Zacks Equity Research

Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.

Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y

by Zacks Equity Research

Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.

Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -212.90% and 94.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Annovis (ANVS) Gains on FDA Authorization for AD Study

by Zacks Equity Research

Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).

Ekta Bagri headshot

LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

by Ekta Bagri

The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.

Prothena (PRTA) Down 16.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus

by Zacks Equity Research

Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of -72.55% and 93.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?

by Zacks Equity Research

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus

by Zacks Equity Research

Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.

Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead?

by Zacks Equity Research

Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.

Prothena (PRTA) IND Application Gets FDA Clearance for AD

by Zacks Equity Research

Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.